Clinical trial
DOSE ADAPTED PERSONALIZED ABLATIVE RADIOTHERAPY OF THE PROSTATE
NCT07578519 is registered in ClinicalTrials.gov with AHS Cancer Control Alberta as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- DOSE ADAPTED PERSONALIZED ABLATIVE RADIOTHERAPY OF THE PROSTATE
- Lead sponsor
- AHS Cancer Control Alberta
- Phase
- Phase 2
- Overall status
- Recruiting
- Start date
- August 26, 2026
- Completion date
- June 30, 2032
- Enrollment
- 50 (estimated)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.
prostate cancer